EGFR tyrosine kinase inhibitors (TKIs, gefitinib, erlotinib, afatinib) are employed for those tumors in which this receptor is overexpressed or constitutively activated by mutations; however, cancer cells are able to escape such inhibition leading to tumor relapse. Here, EGFR is linked to neoplasm.